Castle Biosciences Inc. (CSTL) Reports Q4 EPS of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results
March 10, 2020 4:05 PM EDT
Q4 2019 recognized revenues of $17.6 million, compared to $11.4 million in Q4 2018
Q4 2019 adjusted revenues of $17.6 million, compared to $6.2 million in Q4 2018
Full-year 2019 revenues of $51.9 million, compared to $22.8 million in 2018
Full-year 2019 gross margin was 86%
2020 revenue guidance of $61-64 million
Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the fourth quarter and twelve months ended December 31,... More
